These drug stocks give you a bright future

Article Excerpt

We think the drug industry will enjoy great success over the next decade. But due to the nature of the business, results will vary widely and unpredictably from one drug company to another. A volatile market like the one we expect for drug stocks will include winners and losers. Here are two that we expect to be among the big winners. ELI LILLY & CO., $453.56, is a #1 Power Buy for 2023. The company (New York symbol LLY; TSINetwork Rating: Above Average) (www.lilly.com; Shares outstanding: 949.3 million; Market cap: $428.3 billion; Dividend yield: 1.0%) researches, develops, manufactures, and markets human pharmaceutical products. In the three months ended March 31, 2023, Lilly’s revenue fell 10.9%, to $6.96 billion from $7.81 billion a year earlier. However, excluding year-earlier COVID-related sales of $1.47 billion, revenue rose 10%. Per-share earnings in the quarter decreased 38.2%, to $1.62 from $2.62. The decline came from the lower revenue. Lilly raised its quarterly dividend by 15.3% with the March 2023 payment. The shares now…